The estimated value of θAND_DS was 6.77 x 10−1, implying that subjects with antiandrogen use within 30 days of leuprorelin initiation was associated with 96.8% higher LHRH treatment effect on killing of drug-sensitive PSA-producing cancer cell population compared to those without antiandrogen use. The gene discussed is KLK3; the disease is cancer.